Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Metformin/voglibose - HK inno.N

Next Previous
Search
Drug Profile

Metformin/voglibose - HK inno.N

Alternative Names: CJ-30001; CJ-30002; HKB-0701/SLM-0807; SLM-0807/HKB-0701; Voglibose/metformin; Vogmet

Latest Information Update: 30 Jun 2020

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator CJ Cheiljedang Corp.
  • Developer HK inno.N
  • Class Antihyperglycaemics; Biguanides; Inositol phosphates; Small molecules; Sugar alcohols
  • Mechanism of Action Alpha-glucosidase inhibitors; AMP activated protein kinase stimulants; Gluconeogenesis inhibitors; Glucose modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Type 2 diabetes mellitus

Most Recent Events

  • 18 Jun 2020 CJ HealthCare is now called HK inno.N
  • 07 Feb 2019 Chemical structure information added
  • 01 Jul 2012 CJ Cheiljedang Corporation completes a phase III trial in Type-2 diabetes mellitus in South Korea (NCT01370707)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top